Citigroup Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price

Key Points

• Citigroup lowered its price target on AbbVie from $235 to $230 and kept a "neutral" rating, implying only about a 1.69% upside from the prior close.
• Broader analyst coverage remains more positive: the consensus rating is a Moderate Buy with an average target of $247.84, and several firms (e.g., Scotiabank $280, Berenberg $275, JPMorgan $260, HSBC $265) have higher targets or upgrades.
• AbbVie recently traded around $226.19 with a market cap near $399.8B; the company beat recent quarterly EPS and revenue estimates (EPS $1.86 vs. $1.77; revenue $15.78B, up 9.1%) and has roughly 70% institutional ownership.

AbbVie (NYSE:ABBV - Get Free Report) had its price objective reduced by equities researchers at Citigroup from $235.00 to $230.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Citigroup's price objective would suggest a potential upside of 1.69% from the stock's previous close.

Several other analysts have also recently commented on the company. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Scotiabank assumed coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a "sector outperform" rating and a $280.00 price target on the stock. HSBC upgraded shares of AbbVie from a "hold" rating to a "buy" rating and increased their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Bank of America boosted their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Finally, JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the stock an "overweight" rating in a report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $247.84.

AbbVie Price Performance

Shares of AbbVie stock traded up $5.42 during trading on Tuesday, hitting $226.19. The company's stock had a trading volume of 1,279,812 shares, compared to its average volume of 7,155,083. AbbVie has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market cap of $399.76 billion, a price-to-earnings ratio of 171.18, a price-to-earnings-growth ratio of 0.90 and a beta of 0.36. The stock has a 50-day moving average price of $225.33 and a two-hundred day moving average price of $217.78.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the company earned $3.00 EPS. AbbVie's revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts predict that AbbVie will post 12.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Conning Inc. grew its stake in AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company's stock valued at $35,458,000 after purchasing an additional 12,690 shares during the last quarter. Diversified Trust Co lifted its holdings in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company's stock worth $13,215,000 after purchasing an additional 10,891 shares during the period. Dohj LLC lifted its holdings in shares of AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company's stock worth $802,000 after purchasing an additional 1,335 shares during the period. Permanent Capital Management LP purchased a new stake in AbbVie in the third quarter valued at approximately $720,000. Finally, Railway Pension Investments Ltd increased its holdings in AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company's stock worth $197,723,000 after buying an additional 211,800 shares during the period. Institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.